US2290436A - Diagnostic composition and method - Google Patents

Diagnostic composition and method Download PDF

Info

Publication number
US2290436A
US2290436A US358480A US35848040A US2290436A US 2290436 A US2290436 A US 2290436A US 358480 A US358480 A US 358480A US 35848040 A US35848040 A US 35848040A US 2290436 A US2290436 A US 2290436A
Authority
US
United States
Prior art keywords
blood
benzidine
tolidine
group
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US358480A
Inventor
Kamlet Jonas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Corp
Original Assignee
Miles Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miles Laboratories Inc filed Critical Miles Laboratories Inc
Priority to US358480A priority Critical patent/US2290436A/en
Application granted granted Critical
Publication of US2290436A publication Critical patent/US2290436A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721Haemoglobin
    • G01N33/725Haemoglobin using peroxidative activity
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/904Oxidation - reduction indicators

Definitions

  • the present invention relates to diagnostic compositions and, more particularly, to diagnostic compositions suitable for use in the qualitative detection and semi-quantitative estimation of blood in body fluids, such as urine, vomitus, gastric contents, semen, cerebrospinal fluid and in feces. It has for its object to provide a simple, rapid and convenient method for performing this test with a high degree of accuracy and specificity, and one that can readily be used by the average physician without laboratory equipment, supplies of fresh chemicals or specialized analytical training.
  • occult blood in body fluids and feces has become an invaluable aid to the medical practitioner in the correct diagnosis of a great number of disorders.
  • Blood is found in the gastric contents and in vomitus in conditions associated with erosion of the mucou membranes, in ulcers and in carcinomas. regular and frequent occurrence of occult blood is suggestive of gastro intestinal cancer, gastric or duodenal ulcers or hemorrhoids. In these conditions, the hemorrhage is often so slight that it is not possible to detect blood by microscopic identifications of the erythrocytes (red blood cells) and a sensitive and specific chemical test for occult blood becomes invaluable.
  • blood cells hematuria or blood pigment hemoglobinuria
  • hematuria or blood pigment hemoglobinuria
  • purpura typhus, scurvy, purpura, pyemia, nephritis, renal calculi, as the re-,- sult of a burn covering a large part of the body, by the action of various hemolytic toxins, etc.
  • the benzidine reaction for the detection of occult blood is based, in general, on the reaction of the peroxidase present in the blood with the hydrogen peroxide or the reagent to form active" oxygen.
  • the benzidine acts as an oxygen acceptor and is readily oxidized to a colored quinonoid form.
  • A, B, C, D, E, F, G and H are members of the group consisting of hydrogen and alkyl radicals, may be used as an oxygen acceptor in the benzidine reaction.
  • Examples of such members are benzidine, orthotolidine, metatoli dine, etc.
  • the present invention has for its further ob ject to provide a means whereby an unskilled tion which remains stable and sensitive over long period of time under all ordinary conditions of temperature and humidity.
  • the basis of the present invention is the finding that such compositions of high sensitivity, good specificity and great stability can be obtained by mixing, in the dry state:
  • A, B, C, D, E, F, G and H are members of the group consisting of hydrogen and alkyl radicals.
  • perborates and persulfates of the alkali metals and the alkali-earth metals will form hydrogen peroxide at a slow and steady rate.
  • one drop of the material to be tested (in the case of feces-an aqueous suspension of the specimen) is deposited on a measured quantity of thedry composition, e. g. a five-grain tablet.
  • a blue or green colored spot will form within a short time. If, after five minutes, there is no change of color, the specimen is free 01' occult blood.
  • the dry composition may be suspended in water and mixed with the material to be tested. In the presence of occult blood, a blue or green color will be obtained within five minutes.
  • a semi-quantitative estimation of the amount of occult blood present in the specimen may be made by measuring the time required for the first definite blue or green coloration to be observable.
  • a definite coloration within thirty seconds is reported as four plus, thirty seconds to one minutethree plus, one minute to two minutestwo plus, two minutes to three minutes-one plus,
  • diluents such as talc, kaolin and gypsum may be added to obtain a tablet with better keeping qualities, or a more stable product.
  • Excipients such as lactose, starch or flour may be added to facilitate the formation of granules.
  • Dispersing agents such as saponin, gelatin, agar, soap, alkali-metal silicates, tragacanth or gum arabic may be added to accelerate the disintegration of the tablet when placed into fluid.
  • compositions such as coloring matters or perfumes may likewise be added.
  • auxiliary agents such as coloring matters or perfumes may likewise be added.
  • they may be covered with a water-dispersible varnish or wax.
  • These compositions may be used in the form or powder, or granules, or dispensed in capsules, or they may be pressed into tablets of such size is convenient for the peri'ormance 01! a sin le te
  • the following examples of typical compositions covered by this invention are intended to define and illustrate but in no way to limit this invention to the reagents, proportions or conditions described therein. Obvious modifications will occur to any *person skilled in the art.
  • Example I Grams Anhydrous granular citric acid 1000 Benzidine, chemically pure 100 Barium peroxide, heavy powder 250 Talc powder 250 are intimately mixed until homogeneous. The mixture is then compressed into five-grain tablets.
  • Example II Grams Sodium acid pyrophosphate 1000 Orthotolidine, chemically pure 50 Sodium perborate monohydrate 200 Kaolin powder 500 are intimately mixed until homogeneous.
  • the sensitivity of this composition is such that it will detect one part of blood in eight hundred thousand parts of urine or one million parts of water.
  • Diagnostic compositions comprising in dry solid form a member of the group consisting oi benzidine, ortho-tolidine and metatolidine, a member of the group consisting of the peroxides, perborates and persulfates of the alka i metals and the alkali-earth metals and a solid compound which contains at least one available acidic hydrogen atom.
  • Diagnostic compositions comprising in dry solid form a member of the group consisting of benzidine, ortho-tolidine and meta-tolidine, barium peroxide and a solid compound which contains at least one available acidic hydrogen atom.
  • Diagnostic compositions comprising in dry solid form a member of the group consisting of benzidine, ortho-tolidine and meta-tolidine, barium peroxide and citric acid.
  • Diagnostic compositions comprising in dry solid form benzidine, barium peroxide and citric acid.
  • Diagonstic compositions comprising in dry solid form orth-tolidine, sodium perborate and sodium acid pyrophosphate.
  • a process for testing for blood in fluids which consists in adding a measured amount or said fiuid to a measured amount of a composition
  • a composition comprising in dry solid form a member of the group consisting of benzidine, ortho-tolidine and meta-tolidine, a member of the group consisting of the peroxides, perborates and persulfates of the alkali metals and the alkali-earth metals, and a solid compound which contains at least one available acidic hydrogen atom, whereby a detectable color-change results.
  • a process for testing for blood in fluids which consists in mixing a measured amount of said fluid with a suspension in water of a measured amount of a composition
  • a composition comprising in dry solid form a member of the group consisting of benzidine, ortho-tolidine and meta-tolidine, a member of the group consisting of the peroxides, perborates and persuliates of the alkali metals and the alkali-earth metals, and a solid compound which contains at least one available acidic hydrogen atom, whereby a detectable color-change results.

Description

Patented July 21, 1942 DIAGNOSTIC COMPOSITION AND .METHOD I Jonas Kamiet, Brooklyn, N. Y., assignor to Miles Laboratories, Inc., Eikhart, Ind., a corporation of Indiana No Drawing.
'lClaims.
The present invention relates to diagnostic compositions and, more particularly, to diagnostic compositions suitable for use in the qualitative detection and semi-quantitative estimation of blood in body fluids, such as urine, vomitus, gastric contents, semen, cerebrospinal fluid and in feces. It has for its object to provide a simple, rapid and convenient method for performing this test with a high degree of accuracy and specificity, and one that can readily be used by the average physician without laboratory equipment, supplies of fresh chemicals or specialized analytical training.
The detection of occult blood in body fluids and feces has become an invaluable aid to the medical practitioner in the correct diagnosis of a great number of disorders. Blood is found in the gastric contents and in vomitus in conditions associated with erosion of the mucou membranes, in ulcers and in carcinomas. regular and frequent occurrence of occult blood is suggestive of gastro intestinal cancer, gastric or duodenal ulcers or hemorrhoids. In these conditions, the hemorrhage is often so slight that it is not possible to detect blood by microscopic identifications of the erythrocytes (red blood cells) and a sensitive and specific chemical test for occult blood becomes invaluable. In the urine, blood cells (hematuria) or blood pigment hemoglobinuria) is found in typhus, scurvy, purpura, pyemia, nephritis, renal calculi, as the re-,- sult of a burn covering a large part of the body, by the action of various hemolytic toxins, etc.
However, the methods heretofore employed for the detection of occult blood require some technical ability, experience and fresh supplies of reagents which are not always available to the average physician. Thus, the benzidine reaction which is capable of great accuracy and is one of the most delicate tests for the detection of occult blood, requires that a fresh solution of benzidine in glacial acetic acid be prepared daily. Since these solutions change rapidly, especially in contact with light, they rapidly lose their sensitivity and must be discarded. (Journal of Biological Chemistry, volume 19, page 445, 1914; Zentralblatt fur Chirurgie, volume 41, No. 28, 1914.)
Ruttan and Hardisty (Canadian Medical Association Journal, Nov. 1912; Biochemical Bulletin, volume 2, page 225, 1913) have described a modification of the benzidine reaction, using o-tolidine dissolved in glacial acetic acid. This solution is said to remain stable for one month. It has, however, been my experience that after one week, the solution of o-tolidine becomes too In the feces, the
Application September 26, 1940, Serial No. 358,480
insensitive for use since it will no longer detect traces of occult blood that will give a definite positive reaction with a fresh o-tolidine solution.
The benzidine reaction for the detection of occult blood is based, in general, on the reaction of the peroxidase present in the blood with the hydrogen peroxide or the reagent to form active" oxygen. The benzidine acts as an oxygen acceptor and is readily oxidized to a colored quinonoid form. In general, any compound of the 7 general formula:
mN o r Ni where A, B, C, D, E, F, G and H are members of the group consisting of hydrogen and alkyl radicals, may be used as an oxygen acceptor in the benzidine reaction. Examples of such members are benzidine, orthotolidine, metatoli dine, etc.
The present invention has for its further ob ject to provide a means whereby an unskilled tion which remains stable and sensitive over long period of time under all ordinary conditions of temperature and humidity. The basis of the present invention is the finding that such compositions of high sensitivity, good specificity and great stability can be obtained by mixing, in the dry state:
(a). A compound of the general formula:
HzN NP:
where A, B, C, D, E, F, G and H are members of the group consisting of hydrogen and alkyl radicals.
(b) A member a of the group comprising the peroxides, perborates and persulfates ofthe alwithout the use of i .sodium bisulfate, etc., etc. Members 01' this group, when reacted in aqueous solution with a member of the group consisting of the peroxides,
perborates and persulfates of the alkali metals and the alkali-earth metals, will form hydrogen peroxide at a slow and steady rate.
To determine qualitatively whether occult blood is present in a specimen, one drop of the material to be tested (in the case of feces-an aqueous suspension of the specimen) is deposited on a measured quantity of thedry composition, e. g. a five-grain tablet. In the presence of blood, a blue or green colored spot will form within a short time. If, after five minutes, there is no change of color, the specimen is free 01' occult blood. Alternatively, the dry composition may be suspended in water and mixed with the material to be tested. In the presence of occult blood, a blue or green color will be obtained within five minutes.
A semi-quantitative estimation of the amount of occult blood present in the specimen may be made by measuring the time required for the first definite blue or green coloration to be observable. A definite coloration within thirty seconds is reported as four plus, thirty seconds to one minutethree plus, one minute to two minutestwo plus, two minutes to three minutes-one plus,
three minutes to five minutes-plus minus. If
no definite coloration is obtained after five minutes, the test is reported as negative.
' It is obvious, of course, that diluents, excipients, dispersing agents, auxiliary substances and coating materials may be incorporated into these compositions without changing the basis of the present invention. Diluents such as talc, kaolin and gypsum may be added to obtain a tablet with better keeping qualities, or a more stable product. Excipients such as lactose, starch or flour may be added to facilitate the formation of granules. Dispersing agents such as saponin, gelatin, agar, soap, alkali-metal silicates, tragacanth or gum arabic may be added to accelerate the disintegration of the tablet when placed into fluid. Auxiliary agents, such as coloring matters or perfumes may likewise be added. To improve the keeping qualitiesof these compositions in tablet form, they may be covered with a water-dispersible varnish or wax. These compositions may be used in the form or powder, or granules, or dispensed in capsules, or they may be pressed into tablets of such size is convenient for the peri'ormance 01! a sin le te The following examples of typical compositions covered by this invention are intended to define and illustrate but in no way to limit this invention to the reagents, proportions or conditions described therein. Obvious modifications will occur to any *person skilled in the art.
Example I Grams Anhydrous granular citric acid 1000 Benzidine, chemically pure 100 Barium peroxide, heavy powder 250 Talc powder 250 are intimately mixed until homogeneous. The mixture is then compressed into five-grain tablets.
The sensitivity of this composition is such that it will detect one part of blood in one million parts of urine or one and a half million parts of water. Example II Grams Sodium acid pyrophosphate 1000 Orthotolidine, chemically pure 50 Sodium perborate monohydrate 200 Kaolin powder 500 are intimately mixed until homogeneous. The
mixture is then compressed into five-grain tablets.
The sensitivity of this composition is such that it will detect one part of blood in eight hundred thousand parts of urine or one million parts of water.
Having described my invention, what I claim and desire to protect by Letters Patent is:
1. Diagnostic compositions comprising in dry solid form a member of the group consisting oi benzidine, ortho-tolidine and metatolidine, a member of the group consisting of the peroxides, perborates and persulfates of the alka i metals and the alkali-earth metals and a solid compound which contains at least one available acidic hydrogen atom.
2. Diagnostic compositions comprising in dry solid form a member of the group consisting of benzidine, ortho-tolidine and meta-tolidine, barium peroxide and a solid compound which contains at least one available acidic hydrogen atom.
3. Diagnostic compositions comprising in dry solid form a member of the group consisting of benzidine, ortho-tolidine and meta-tolidine, barium peroxide and citric acid.
4. Diagnostic compositions comprising in dry solid form benzidine, barium peroxide and citric acid.
5. Diagonstic compositions comprising in dry solid form orth-tolidine, sodium perborate and sodium acid pyrophosphate.
6. A process for testing for blood in fluids which consists in adding a measured amount or said fiuid to a measured amount of a composition comprising in dry solid form a member of the group consisting of benzidine, ortho-tolidine and meta-tolidine, a member of the group consisting of the peroxides, perborates and persulfates of the alkali metals and the alkali-earth metals, and a solid compound which contains at least one available acidic hydrogen atom, whereby a detectable color-change results.
7. A process for testing for blood in fluids which consists in mixing a measured amount of said fluid with a suspension in water of a measured amount of a composition comprising in dry solid form a member of the group consisting of benzidine, ortho-tolidine and meta-tolidine, a member of the group consisting of the peroxides, perborates and persuliates of the alkali metals and the alkali-earth metals, and a solid compound which contains at least one available acidic hydrogen atom, whereby a detectable color-change results.
JONAS KAMLET.
US358480A 1940-09-26 1940-09-26 Diagnostic composition and method Expired - Lifetime US2290436A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US358480A US2290436A (en) 1940-09-26 1940-09-26 Diagnostic composition and method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US358480A US2290436A (en) 1940-09-26 1940-09-26 Diagnostic composition and method

Publications (1)

Publication Number Publication Date
US2290436A true US2290436A (en) 1942-07-21

Family

ID=23409819

Family Applications (1)

Application Number Title Priority Date Filing Date
US358480A Expired - Lifetime US2290436A (en) 1940-09-26 1940-09-26 Diagnostic composition and method

Country Status (1)

Country Link
US (1) US2290436A (en)

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2436814A (en) * 1943-06-08 1948-03-02 James L Leitch Ortho-tolidine tablet composition
US2569663A (en) * 1947-12-31 1951-10-02 Dearborn Chemicals Co Composition for and method of determining chromate concentrations
US2606102A (en) * 1946-12-03 1952-08-05 Allied Chem & Dye Corp Test strips for detecting low concentrations of chlorine in air
US2606101A (en) * 1946-12-03 1952-08-05 Allied Chem & Dye Corp Process and apparatus for promptly detecting chlorine gas leaks from chlorine containers
US2676874A (en) * 1949-09-27 1954-04-27 Devine John Berchmans Method of and means for the rapid approximate quantitative estimation of chloride concentration in aqueous liquids
US2799660A (en) * 1954-04-15 1957-07-16 Miles Lab Blood test composition and method
US2838377A (en) * 1950-03-09 1958-06-10 Miles Lab Blood test
US2905594A (en) * 1956-04-25 1959-09-22 Herman J Morris Means for detecting enzyme activity
US2907638A (en) * 1956-09-24 1959-10-06 Robert L Dryer Apparatus for quantitative isothermal distillation
US3252762A (en) * 1961-05-04 1966-05-24 Miles Lab Stabilized occult blood diagnostic
FR2295425A1 (en) * 1974-12-21 1976-07-16 Boehringer Mannheim Gmbh APPLICATION OF 3,3,5,5-TETRA-ALCOYLBENZIDINE DERIVATIVES AS OXIDATION INDICATORS IN RAPID TESTS
FR2320553A1 (en) * 1975-08-06 1977-03-04 Riedel De Haen Ag DIAGNOSIS AGENT FOR THE DETECTION OF BLOOD AND OTHER SUBSTANCES WITH PEROXIDATIVE EFFECT IN BODY FLUIDS
FR2386823A1 (en) * 1977-04-09 1978-11-03 Boehringer Mannheim Gmbh STABILIZED DIAGNOSTIC AGENTS CONTAINING OXIDATION INDICATORS
US4132527A (en) * 1974-01-09 1979-01-02 Shionogi & Co., Ltd. Diagnostic compositions, diagnosing instruments, and methods of manufacturing same
US4148611A (en) * 1978-06-28 1979-04-10 Miles Laboratories, Inc. Test composition, device and method for the detection of peroxidatively active substances
US4175923A (en) * 1978-06-26 1979-11-27 Friend William G Method and apparatus for occult blood testing in the home
FR2449727A1 (en) * 1979-02-23 1980-09-19 Miles Lab ANALYTICAL COMPOSITION BASED ON GLUCOSE OXIDASE, DEVICE AND METHOD FOR DETERMINING GLUCOSE IN A SAMPLE OF BODY LIQUID
US4526869A (en) * 1980-09-24 1985-07-02 Regents Of The University Of Minnesota Method for quantitatively determining the concentration of hemoglobin in a biological sample
US4673654A (en) * 1985-10-31 1987-06-16 Warner-Lambert Company Composition for determining peroxidase-like activity of hemoglobin
US4676950A (en) * 1984-02-03 1987-06-30 Foster Research Corporation Indicator and test device for detecting occult blood
US4939097A (en) * 1986-06-02 1990-07-03 Litmus Concepts, Inc. Fecal occult blood test methods
US4956300A (en) * 1982-01-05 1990-09-11 Helena Laboratories Corporation Aid for determining the presence of occult blood, method of making the aid, and method of using the aid
US5053342A (en) * 1987-12-24 1991-10-01 Litmus Concepts, Inc. Fecal occult blood test reagents
US5081040A (en) * 1987-06-29 1992-01-14 Helena Laboratories Corporation Composition and kit for testing for occult blood in human and animal excretions, fluids, or tissue matrixes
US5196167A (en) * 1989-04-04 1993-03-23 Helena Laboratories Corporation Fecal occult blood test product with positive and negative controls
US5217874A (en) * 1989-04-04 1993-06-08 Helena Laboratories Corporation Fecal occult blood test product with positive and negative controls
US5273888A (en) * 1984-01-16 1993-12-28 Helena Laboratories Corporation Chemical test kit and method for determining the presence of blood in a specimen and for verifying the effectiveness of the chemicals
US5702913A (en) * 1983-12-21 1997-12-30 Helena Laboratories Corporation Chromgen-reagent test system
US20040214244A1 (en) * 2003-04-25 2004-10-28 Idexx Laboratories, Inc. Detection of analytes in fecal samples

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2436814A (en) * 1943-06-08 1948-03-02 James L Leitch Ortho-tolidine tablet composition
US2606102A (en) * 1946-12-03 1952-08-05 Allied Chem & Dye Corp Test strips for detecting low concentrations of chlorine in air
US2606101A (en) * 1946-12-03 1952-08-05 Allied Chem & Dye Corp Process and apparatus for promptly detecting chlorine gas leaks from chlorine containers
US2569663A (en) * 1947-12-31 1951-10-02 Dearborn Chemicals Co Composition for and method of determining chromate concentrations
US2676874A (en) * 1949-09-27 1954-04-27 Devine John Berchmans Method of and means for the rapid approximate quantitative estimation of chloride concentration in aqueous liquids
US2838377A (en) * 1950-03-09 1958-06-10 Miles Lab Blood test
US2799660A (en) * 1954-04-15 1957-07-16 Miles Lab Blood test composition and method
US2905594A (en) * 1956-04-25 1959-09-22 Herman J Morris Means for detecting enzyme activity
US2907638A (en) * 1956-09-24 1959-10-06 Robert L Dryer Apparatus for quantitative isothermal distillation
US3252762A (en) * 1961-05-04 1966-05-24 Miles Lab Stabilized occult blood diagnostic
US4132527A (en) * 1974-01-09 1979-01-02 Shionogi & Co., Ltd. Diagnostic compositions, diagnosing instruments, and methods of manufacturing same
FR2295425A1 (en) * 1974-12-21 1976-07-16 Boehringer Mannheim Gmbh APPLICATION OF 3,3,5,5-TETRA-ALCOYLBENZIDINE DERIVATIVES AS OXIDATION INDICATORS IN RAPID TESTS
US4385114A (en) * 1974-12-21 1983-05-24 Boehringer Mannheim Gmbh Oxidation indicators comprising 3,3',5,5'-tetraalkylbenzidine compounds
FR2320553A1 (en) * 1975-08-06 1977-03-04 Riedel De Haen Ag DIAGNOSIS AGENT FOR THE DETECTION OF BLOOD AND OTHER SUBSTANCES WITH PEROXIDATIVE EFFECT IN BODY FLUIDS
FR2386823A1 (en) * 1977-04-09 1978-11-03 Boehringer Mannheim Gmbh STABILIZED DIAGNOSTIC AGENTS CONTAINING OXIDATION INDICATORS
US4175923A (en) * 1978-06-26 1979-11-27 Friend William G Method and apparatus for occult blood testing in the home
US4148611A (en) * 1978-06-28 1979-04-10 Miles Laboratories, Inc. Test composition, device and method for the detection of peroxidatively active substances
FR2449727A1 (en) * 1979-02-23 1980-09-19 Miles Lab ANALYTICAL COMPOSITION BASED ON GLUCOSE OXIDASE, DEVICE AND METHOD FOR DETERMINING GLUCOSE IN A SAMPLE OF BODY LIQUID
US4526869A (en) * 1980-09-24 1985-07-02 Regents Of The University Of Minnesota Method for quantitatively determining the concentration of hemoglobin in a biological sample
US4956300A (en) * 1982-01-05 1990-09-11 Helena Laboratories Corporation Aid for determining the presence of occult blood, method of making the aid, and method of using the aid
US5702913A (en) * 1983-12-21 1997-12-30 Helena Laboratories Corporation Chromgen-reagent test system
US5273888A (en) * 1984-01-16 1993-12-28 Helena Laboratories Corporation Chemical test kit and method for determining the presence of blood in a specimen and for verifying the effectiveness of the chemicals
US4676950A (en) * 1984-02-03 1987-06-30 Foster Research Corporation Indicator and test device for detecting occult blood
AU588391B2 (en) * 1985-10-31 1989-09-14 Warner-Lambert Company Composition and method for determining peroxidase-like activity of hemoglobin
US4673654A (en) * 1985-10-31 1987-06-16 Warner-Lambert Company Composition for determining peroxidase-like activity of hemoglobin
US4939097A (en) * 1986-06-02 1990-07-03 Litmus Concepts, Inc. Fecal occult blood test methods
US5081040A (en) * 1987-06-29 1992-01-14 Helena Laboratories Corporation Composition and kit for testing for occult blood in human and animal excretions, fluids, or tissue matrixes
US5053342A (en) * 1987-12-24 1991-10-01 Litmus Concepts, Inc. Fecal occult blood test reagents
US5196167A (en) * 1989-04-04 1993-03-23 Helena Laboratories Corporation Fecal occult blood test product with positive and negative controls
US5217874A (en) * 1989-04-04 1993-06-08 Helena Laboratories Corporation Fecal occult blood test product with positive and negative controls
US20040214244A1 (en) * 2003-04-25 2004-10-28 Idexx Laboratories, Inc. Detection of analytes in fecal samples

Similar Documents

Publication Publication Date Title
US2290436A (en) Diagnostic composition and method
US3290117A (en) Occult blood diagnostic composition with color enhancing agent
US3472738A (en) Test implement for detecting peroxidase
US3652222A (en) Bilirubin assay
US3814586A (en) Composition,method and device for determining bilirubin and urobilinogen
CN106248862A (en) A kind of chloride ion conductor method in polycarboxylate water-reducer
US2186902A (en) Urine acetone test
Girotti et al. Determination of superoxide dismutase in erythrocytes by a chemiluminescent assay
US4719181A (en) Free flowing granular indicator material for peroxidase-like activity
US2999052A (en) Composition for colorimetric test for serum enzymes
JP3157827B2 (en) Diagnostic test
JPS59212457A (en) Novel compound useful for detecting ion and manufacture
US3526479A (en) Diagnostic article and method for detection therewith
KR920007201B1 (en) Process and compounds for detecting of peritonitis
Aldridge et al. A new method for the micro-determination of beryllium with particular reference to its determination in biological materials
Ratnaike et al. Blood ammonia measurement using a simple reflectometer
JPH03505628A (en) Reducing indicator containing pyrogallol and its use
JPS585190A (en) Production of purified animal origin uricase active substance used in measuring uric acid in sample
US3592741A (en) Method for analysis of urea
US4717652A (en) Composition for detection of peritoneal inflammation or infection
EP0243125A2 (en) Method of measuring phenol and alpha-naphthol, and method of measuring the activity of enzymes
JPS6010261B2 (en) Composition for detecting occult blood
Aldrich Cholinesterase assays: Their usefulness in diagnosis of anticholinesterase intoxications
Cossar et al. Evaluation of a kit for serum calcium determination
JPS60225062A (en) Stabilizer for nrea nitrogen color identification reagent